Formoterol therapy for chronic obstructive pulmonary disease: A review of the literature

Pharmacotherapy

Volumn 22, Issue 9 I, 2002, Pages 1129-1139

  Friedman, Mitchell ^a   Cioppa, Giovanni Della ^b   Kottakis, John ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE;

BETA ADRENERGIC STIMULATION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEADACHE; HEALTH STATUS; HEART ARRHYTHMIA; HUMAN; MUSCLE CRAMP; PHARYNGITIS; PRURITUS; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; XEROSTOMIA; PATHOPHYSIOLOGY; SPIROMETRY;

ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS; ETHANOLAMINES; HUMAN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; SUPPORT, NON-U.S. GOV'T; THEOPHYLLINE; HUMANS;

EID: 0036708214     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.13.1129.33523     Document Type: Review

References (34)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD). Workshop summary
2. 1: The lung health story
3. ATS statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
4. BTS guidelines for the management of chronic obstructive pulmonary disease
5. Formoterol: A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease
6. Formoterol: An update of its pharmacological properties and therapeutic efficacy in the management of asthma
7. Sustained bronchoprotection, bronchodilation, and symptom control during regular formoterol use in asthma of moderate or greater severity
8. Effect of inhaled formoterol and budesonide on exacerbations of asthma
9. Clinical experience over five years of daily therapy with formoterol in patients with bronchial asthma
10. Formoterol - Where does it fit in the current guidelines?
11. 2-adrenoceptor agonist bronchodilator
12. 2-adrenergic agonists in COPD
13. Rapid onset of bronchodilation in COPD: A placebo-controlled study comparing formoterol (Foradil Aerolizerr®) with salbutamol (Ventodisk™)
14. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease
15. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease
16. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD
17. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A rossover, placebo-controlled comparison of onset and duration of action
18. 2-agonists for COPD
19. Measuring functional status in chronic lung disease: Conclusions from a randomized control trial
20. Changes in dyspnea, health status, and lung function in chronic airway disease
21. Spirometry and dyspnea in patients with COPD: When small differences mean little
22. Health related quality of life (HRQL) and the use of formoterol in patients with COPD
23. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium
24. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD
25. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease
26. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: A dose-response study
27. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: Results of a randomized, double-blind clinical study
28. Formoterol Turbuhaler (F) versus salmeterol Diskus (S) in patients with partially reversible stable COPD
29. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD
30. Formoterol as dry powder inhalation: A dose finding study in comparison with formoterol metered dose inhaler and placebo
31. Cardiac effects of ormoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
32. The cardiac safety profile of formoterol dry powder is similar to placebo in patients with COPD
33. Formoterol Turbuhaler® for as-needed therapy in patients with mild acute exacerbations of COPD